NO20006633L - Preparat som omfatter <beta>-hydroksy-<beta>-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse - Google Patents

Preparat som omfatter <beta>-hydroksy-<beta>-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse

Info

Publication number
NO20006633L
NO20006633L NO20006633A NO20006633A NO20006633L NO 20006633 L NO20006633 L NO 20006633L NO 20006633 A NO20006633 A NO 20006633A NO 20006633 A NO20006633 A NO 20006633A NO 20006633 L NO20006633 L NO 20006633L
Authority
NO
Norway
Prior art keywords
beta
preparations
hydroxy
methods
amino acid
Prior art date
Application number
NO20006633A
Other languages
English (en)
Other versions
NO329914B1 (no
NO20006633D0 (no
Inventor
Steven L Nissen
Naji M Abumrad
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22292520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006633(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Publication of NO20006633D0 publication Critical patent/NO20006633D0/no
Publication of NO20006633L publication Critical patent/NO20006633L/no
Publication of NO329914B1 publication Critical patent/NO329914B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20006633A 1998-06-23 2000-12-22 Preparat som omfatter <beta>-hydroksy-<beta>-metylsmorsyre, L-glutamin og L-arginin, og anvendelse av preparatet til fremstilling av et ernaeringspreparat NO329914B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,941 US6031000A (en) 1998-06-23 1998-06-23 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
PCT/US1999/014097 WO1999066917A2 (en) 1998-06-23 1999-06-23 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid

Publications (3)

Publication Number Publication Date
NO20006633D0 NO20006633D0 (no) 2000-12-22
NO20006633L true NO20006633L (no) 2001-02-20
NO329914B1 NO329914B1 (no) 2011-01-24

Family

ID=22292520

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20006633A NO329914B1 (no) 1998-06-23 2000-12-22 Preparat som omfatter <beta>-hydroksy-<beta>-metylsmorsyre, L-glutamin og L-arginin, og anvendelse av preparatet til fremstilling av et ernaeringspreparat
NO20101440A NO332374B1 (no) 1998-06-23 2010-10-18 Preparat som omfatter beta-hydroksy-beta-metylsmorsyre, L-arginin og L-lysin, og anvendelse av preparatet til fremstilling av ernaeringspreparater for bruk til dyr

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20101440A NO332374B1 (no) 1998-06-23 2010-10-18 Preparat som omfatter beta-hydroksy-beta-metylsmorsyre, L-arginin og L-lysin, og anvendelse av preparatet til fremstilling av ernaeringspreparater for bruk til dyr

Country Status (12)

Country Link
US (1) US6031000A (no)
EP (1) EP1089726B1 (no)
JP (2) JP5064609B2 (no)
AU (1) AU756353B2 (no)
CA (1) CA2334761C (no)
DE (1) DE69901396T2 (no)
DK (1) DK1089726T3 (no)
ES (1) ES2177293T3 (no)
NO (2) NO329914B1 (no)
NZ (1) NZ508395A (no)
PL (1) PL195623B1 (no)
WO (1) WO1999066917A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362350B2 (ja) * 1997-10-16 2003-01-07 味の素株式会社 反芻動物の肥育方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20080317886A1 (en) * 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
DK1957061T3 (da) * 2005-11-30 2011-07-25 Novartis Pharma Gmbh Kombination omfattende mindst én aminosyre og en PKR-inhibitor til anvendelse i behandlingen af muskelsvind
TWI424840B (zh) 2005-12-19 2014-02-01 Abbott Lab β-羥基-β-甲基丁酸酯之用途
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) * 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) * 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
CA2746420C (en) * 2008-12-09 2019-11-12 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
DK2391363T3 (en) * 2009-01-29 2017-01-16 Young Hee Ko COMPOSITIONS AND PROCEDURES FOR TREATING CANCER
EP2289555A1 (en) * 2009-08-24 2011-03-02 OrgaNext Research B.V. Method of treating frailty
EP2512236B1 (en) * 2009-12-18 2016-10-19 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
PE20121730A1 (es) 2010-01-29 2013-01-13 Abbott Lab Liquidos nutricionales envasados asepticamente que comprenden beta-hidroxi-beta-metilbutirato (hmb)
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2773363A1 (en) 2011-11-03 2014-09-10 University of Florida Research Foundation, Inc. Nutritional supplement for weight management
CN103945858A (zh) * 2011-11-21 2014-07-23 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
MX2014008521A (es) 2012-01-11 2014-08-21 Abbott Lab Combinacion de beta-hidroxi-beta-metil-butirato, arginina y glutamina, para usarse en el tratamiento de ulceras diabeticas.
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
PL3733171T3 (pl) 2012-09-10 2024-03-18 Metabolic Technologies, LLC Kompozycje zawierające hmb i atp oraz ich zastosowanie
CN104780786A (zh) 2012-09-21 2015-07-15 雅培制药有限公司 包括β-羟基-β-甲基丁酸钙、蛋白质和低水平的电解质的营养组合物
WO2014047493A1 (en) * 2012-09-21 2014-03-27 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein
BR112015010947A2 (pt) 2012-11-13 2018-06-05 Nusirt Sciences Inc composições e métodos para aumentar o metabolismo energético.
CA2904119C (en) * 2013-03-14 2018-01-02 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
BR112015023310A2 (pt) 2013-03-15 2017-07-18 Nusirt Sciences Inc composições, métodos e kits para redução de níveis lipídicos
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
WO2015131152A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
CN107847759A (zh) * 2015-06-01 2018-03-27 代谢科技有限公司 用于减少脂肪量的β‑羟基‑β‑甲基丁酸(HMB)的组合物和使用方法
PT3349745T (pt) 2015-09-16 2024-03-18 Metabolic Tech Inc Composições e métodos de utilização de beta-hidroxi-beta metilbutirato (hmb) para melhorar a recuperação de traumatismos de tecidos moles
KR20180088809A (ko) * 2015-11-19 2018-08-07 가부시키가이샤 오츠카 세이야쿠 코죠 3-히드록시이소발레르산의 1가 양이온염의 결정 및 그 결정의 제조 방법
BR122023026038A2 (pt) 2016-01-21 2024-01-16 Metabolic Technologies, Inc. Usos de um ácido e de um modulador de autofagia e de lipofagia
CA3021784A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
SG11201811493UA (en) 2016-06-24 2019-01-30 Otsuka Pharma Factory Inc Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
AU2017345598B2 (en) 2016-10-21 2023-11-30 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) and probiotics
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3668499A1 (en) 2017-08-14 2020-06-24 Axcella Health Inc. Amino acid compositions for the treatment of liver disease
MX2020007008A (es) * 2018-01-05 2021-04-28 Texas Tech Univ Office Of Research Commercialization COMPOSICIONES Y MÉTODOS DE USO DE ß- HIDROXI-ß-METILBUTIRATO (HMB) ASOCIADO CON AYUNO INTERMITENTE.
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
DE69327468T2 (de) * 1992-09-16 2000-05-11 Univ Iowa State Res Found Inc Verfahren zur reduktion der blutspiegel von gesamtcholesterin und ldl-cholesterin
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
AU6102994A (en) * 1993-02-11 1994-08-29 Iowa State University Research Foundation Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE29707308U1 (de) * 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus

Also Published As

Publication number Publication date
CA2334761C (en) 2009-04-28
PL344589A1 (en) 2001-11-05
NO329914B1 (no) 2011-01-24
AU756353B2 (en) 2003-01-09
PL195623B1 (pl) 2007-10-31
DK1089726T3 (da) 2002-07-22
WO1999066917A2 (en) 1999-12-29
CA2334761A1 (en) 1999-12-29
US6031000A (en) 2000-02-29
EP1089726A2 (en) 2001-04-11
JP2012102118A (ja) 2012-05-31
NZ508395A (en) 2003-09-26
AU4708099A (en) 2000-01-10
NO20006633D0 (no) 2000-12-22
DE69901396D1 (de) 2002-06-06
NO20101440L (no) 2001-02-20
NO332374B1 (no) 2012-09-10
JP2002518440A (ja) 2002-06-25
JP5690261B2 (ja) 2015-03-25
EP1089726B1 (en) 2002-05-02
DE69901396T2 (de) 2002-08-29
JP5064609B2 (ja) 2012-10-31
ES2177293T3 (es) 2002-12-01
WO1999066917A3 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
NO20006633D0 (no) Preparat som omfatter &lt;beta&gt;-hydroksy-&lt;beta&gt;-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse
DK0965578T3 (da) Hidtil ukendt triglycerik og præparat, som omfatter dette
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20001102L (no) 2,3-diaryl-pyrazolo[1,5-B]pyridazinderivater, deres fremstilling og anvendelse som cyklo-oksygenase 2 (COX-2) inhibitorer
NO307335B1 (no) Substituerte N-(indol-2-karbonyl)-&lt;beta&gt;-alaninamider, anvendelse derav og farmasøytisk preparat
DK0799052T3 (da) Ny antihrombotisk formulering, fremgangsmåde til dens fremstilling og anvendelse deraf
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO20015859L (no) A-&lt;beta&gt;-peptidpreparater og fremgangsmåte for fremstilling av slike
DK1216247T3 (da) Imidazoimidazoler og triazoler som anti-inflammatoriske midler
EE200000720A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
DK1036794T3 (da) 2-Aryl-8-oxodihydropurinderivater, fremgangsmåde til fremstilling af samme, medicinske præparater indeholdende samme og mellemprodukter deraf
NO20004353L (no) Nye pyridazinderivater og medikamenter inneholdende disse som aktive ingredienser
NO20010078L (no) Fenoksyeddiksyrederivat og farmasøytisk sammensetning omfattende det samme
DK1538160T3 (da) Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
NO307049B1 (no) Forbindelse som er &lt;Beta&gt;-adrenergiske agonister, anvendelse derav og farmasøytisk blanding
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
DK1006110T3 (da) Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler
NO994671D0 (no) Aryl- eller heteroarylsulfonamid-substituerte hydroksamsyrederivater, fremgangsmaate til fremstillint derav og deres anvendelse som farmasöytika
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20003070D0 (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
NO20005173D0 (no) Gen som koder for heliomicin og anvendelse derav
NO20002181D0 (no) Steriliseringsinnpakning, anvendelse derav og fremgangsmÕte for sterilisering
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene

Legal Events

Date Code Title Description
MK1K Patent expired